Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,000 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $66.15 on Friday. The stock’s 50-day moving average is $67.42 and its two-hundred day moving average is $76.44. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm has a market cap of $39.02 billion, a price-to-earnings ratio of 9.55, a PEG ratio of 3.74 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the business earned $0.59 earnings per share. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. Analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in EW. Crewe Advisors LLC purchased a new position in Edwards Lifesciences in the 1st quarter valued at $28,000. First Community Trust NA purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at about $29,000. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth about $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at about $32,000. Finally, Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Barclays decreased their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Morgan Stanley restated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Citigroup dropped their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a report on Tuesday, October 1st. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.